1. Clinical applications of AMH measurements have been proposed for a variety of indications. Measurement of serum AMH is mainly used for assessment of ovarian reserve reflecting the number of antral and pre-antral follicles, the antral follicle count (AFC), and for the predicted response to controlled ovarian stimulation. Further clinical applications of AMH disorders of sex development (DSD) in children and monitoring of granulosa cell tumors to detect residual or recurrent disease. AMH has been suggested as a surrogate biomarker for AFC in the diagnosis of polycystic ovary syndrome (PCOS) and for the prediction of time to menopause.
2. Serum AMH levels decrease significantly during the use of combined contraceptives.
3. This AMH value in pmol/L was generated with the Elecsys AMH Plus assay and is suitable for the individualized dosing of follitropin delta of Ferring.
4. Falsely decreased results may be seen in patients on high doses of biotin (i.e. > 5mg/day). Samples should only be collected from these patients at least 8 hours following the last biotin administration so as to avoid potential interference.